- Posts by Kelsey J. McElveenOfficer
As a member of the firm’s Intellectual Property Litigation group, Kelsey focuses her practice on patent litigation under the Hatch-Waxman Act. After nearly a decade of experience working on Abbreviated New Drug Application ...
The U.S. Supreme Court recently issued its decision in Amgen Inc. v. Sanofi; a decision long-awaited by patent practitioners. In its decision, the Court unanimously held that several of Amgen’s patent claims to a class of antibodies were invalid for lack of enablement.